ImmunoCellular Therapeutics achieves key milestone in stem-to-t-cell research program
ImmunoCellular announced it has achieved a key milestone in its research-stage Stem-to-T-Cell immuno-oncology program. The milestone represents an important step toward stimulating the patient's immune system to produce an unlimited supply of killer T cells that destroy tumor cells. December 13, 2017